Literature DB >> 12892257

Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine.

C C Mok1, C H To, M L Szeto.   

Abstract

Interstitial lung disease (ILD) is a major complication of idiopathic inflammatory myopathies (IIM). We report the successful use of oral cyclophosphamide, followed by azathioprine maintenance, in the treatment of a patient with dermatomyositis-related rapidly deteriorating ILD, resistant to steroid. Prompt recognition and early aggressive immunosuppressive therapy may improve the outlook of this condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892257     DOI: 10.1080/03009740310002542

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 2.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

Review 3.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

4.  Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.

Authors:  Eun Ha Kang; Ran Nakashima; Tsuneyo Mimori; Jinhyun Kim; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  BMC Musculoskelet Disord       Date:  2010-09-28       Impact factor: 2.362

Review 5.  Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hidenaga Kawasumi; Takahisa Gono; Yasushi Kawaguchi; Hisashi Yamanaka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-07-23

Review 6.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

7.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.